Elderly begin to drop out of Novavax vaccine trial to get Pfizer and Moderna shots
(Washington Post Business)

States have responded to the slow rollout of coronavirus vaccine by expanding eligibility for the shots to people over 65. But the moves have made it more difficult to recruit and retain test subjects for clinical trials of vaccines that have yet to win emergency authorization.